Clinical Trial Update: 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pemetrexed plus sorafenib for recurrent or metastatic triple negative breast cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Pemetrexed (pemetrexed)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-07-14